These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33493383)

  • 41. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
    Prado-Garcia H; Romero-Garcia S; Puerto-Aquino A; Rumbo-Nava U
    Cancer Immunol Immunother; 2017 Jun; 66(6):765-776. PubMed ID: 28289860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unusual clear cell variant of epithelioid mesothelioma.
    Dessy E; Falleni M; Braidotti P; Del Curto B; Panigalli T; Pietra GG
    Arch Pathol Lab Med; 2001 Dec; 125(12):1588-90. PubMed ID: 11735696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Tajarernmuang P; Aliaga F; Alwakeel AJ; Tavaziva G; Turner K; Menzies D; Wang H; Ofiara L; Benedetti A; Gonzalez AV
    Chest; 2024 Feb; 165(2):461-474. PubMed ID: 37739030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
    Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
    Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
    Lee HS; Hamaji M; Palivela N; Jang HJ; Splawn T; Ramos D; Lee AK; Raghuram AC; Ramineni M; Amos CI; Ripley RT; Burt BM
    Ann Thorac Surg; 2021 Nov; 112(5):1575-1583. PubMed ID: 33248997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
    Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
    Pak MG; Roh MS
    Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
    Zhang F; Gong W
    Int Immunopharmacol; 2020 Jun; 83():106481. PubMed ID: 32339986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
    J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
    de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
    J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
    Tseng YH; Ho HL; Lai CR; Luo YH; Tseng YC; Whang-Peng J; Lin YH; Chou TY; Chen YM
    J Thorac Oncol; 2018 Mar; 13(3):447-453. PubMed ID: 29246835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.